Search

Your search keyword '"Gambini, D"' showing total 226 results
Start Over Author "Gambini, D"
226 results on '"Gambini, D"'

3. RNAscope in situ hybridization and RT-PCR for detection of SARS-CoV-2 in chilblain-like lesions: A clinical, laboratory and histopathological study

Author

Robustelli Test, E, Sena, P, Locatelli, A, Carugno, A, di Mercurio, M, Moggio, E, Gambini, D, Arosio, M, Callegaro, A, Morotti, D, Gianatti, A, Vezzoli, P, Robustelli Test E., Sena P., Locatelli A. G., Carugno A., di Mercurio M., Moggio E., Gambini D., Arosio M. E. G., Callegaro A., Morotti D., Gianatti A., Vezzoli P., Robustelli Test, E, Sena, P, Locatelli, A, Carugno, A, di Mercurio, M, Moggio, E, Gambini, D, Arosio, M, Callegaro, A, Morotti, D, Gianatti, A, Vezzoli, P, Robustelli Test E., Sena P., Locatelli A. G., Carugno A., di Mercurio M., Moggio E., Gambini D., Arosio M. E. G., Callegaro A., Morotti D., Gianatti A., and Vezzoli P.

Abstract

Background: Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, an increasing number of chilblain-like lesions (ChLL) have been increasingly reported worldwide. To date, the causal link between ChLL and SARS-CoV-2 infection has not been unequivocally established. Methods: In this case series, we present demographic, clinical, laboratory, and histopathological information regarding 27 young patients with a clinical diagnosis of ChLL who referred to the Dermatology Unit of Papa Giovanni XXIII Hospital, Bergamo, Italy, from 1 April 2020 to 1 June 2020. Results: The mean age was 14.2 years, and 21 patients (78%) experienced mild systemic symptoms a median of 28 days before the onset of cutaneous lesions. ChLL mostly involved the feet (20 patients – 74%). Among acral lesions, we identified three different clinical patterns: (i) chilblains in 20 patients (74%); (ii) fixed erythematous macules in 4 children (15%); (iii) erythrocyanosis in 3 female patients (11%). Blood examinations and viral serologies, including parvovirus B19, cytomegalovirus (CMV), Epstein-Barr virus (EBV), and coxsackievirus were normal in all. Three patients (11%) underwent nasopharyngeal swab for RT-PCR for SARS-CoV-2 showing only 1 positive. Histopathological examinations of 7 skin biopsies confirmed the clinical diagnosis of chilblains; vessel thrombi were observed only in 1 case. Our findings failed to demonstrate the direct presence of SARS-CoV-2 RNA in skin biopsies, both with real-time polymerase chain reaction (RT-PCR) and RNAscope in situ hybridization (ISH). Limitations: Limited number of cases, unavailability of laboratory confirmation of COVID-19 in all patients, potential methodological weakness, and latency of skin biopsies in comparison to cutaneous lesions onset. Conclusions: These observations may support the hypothesis of an inflammatory pathogenesis rather than the presence of peripheral viral particles. Although, we could not exclude an early phase of viral end

Published
2022

4. Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study

Author

Russo, F, Galluzzo, M, Stingeni, L, Persechino, S, Zichichi, L, Conti, A, Giofrè, C, Dini, V, Vispi, M, Atzori, L, Cattaneo, A, Parodi, A, Bardazzi, F, Stinco, G, Dapavo, P, Girolomoni, G, Musumeci, M, Papini, M, Venturini, M, Dastoli, S, Di Nuzzo, S, Fargnoli, M, Pagnanelli, G, Bernardini, N, Gambini, D, Malagoli, P, Mazzatenta, C, Peris, K, Zalaudek, I, Fabbrocini, G, Loconsole, F, Vassallo, C, Pietroleonardo, L, Prignano, F, Franchi, C, Offidani, A, Bonifati, C, Di Lernia, V, Gigante, G, Bartezaghi, M, Franchi, M, Ursoleo, P, Aloisi, E, Russo, Filomena, Galluzzo, Marco, Stingeni, Luca, Persechino, Severino, Zichichi, Leonardo, Conti, Andrea, Giofrè, Claudia, Dini, Valentina, Vispi, Martina, Atzori, Laura, Cattaneo, Angelo, Parodi, Aurora, Bardazzi, Federico, Stinco, Giuseppe, Dapavo, Paolo, Girolomoni, Giampiero, Musumeci, Maria Letizia, Papini, Manuela, Venturini, Marina, Dastoli, Stefano, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Pagnanelli, Gianluca, Bernardini, Nicoletta, Gambini, Daniele, Malagoli, Piergiorgio, Mazzatenta, Carlo, Peris, Ketty, Zalaudek, Iris, Fabbrocini, Gabriella, Loconsole, Francesco, Vassallo, Camilla, Pietroleonardo, Lucia, Prignano, Francesca, Franchi, Chiara, Offidani, Anna Maria, Bonifati, Claudio, Di Lernia, Vito, Gigante, Giovanni, Bartezaghi, Marta, Franchi, Matteo, Ursoleo, Paola, Aloisi, Elisabetta, Russo, F, Galluzzo, M, Stingeni, L, Persechino, S, Zichichi, L, Conti, A, Giofrè, C, Dini, V, Vispi, M, Atzori, L, Cattaneo, A, Parodi, A, Bardazzi, F, Stinco, G, Dapavo, P, Girolomoni, G, Musumeci, M, Papini, M, Venturini, M, Dastoli, S, Di Nuzzo, S, Fargnoli, M, Pagnanelli, G, Bernardini, N, Gambini, D, Malagoli, P, Mazzatenta, C, Peris, K, Zalaudek, I, Fabbrocini, G, Loconsole, F, Vassallo, C, Pietroleonardo, L, Prignano, F, Franchi, C, Offidani, A, Bonifati, C, Di Lernia, V, Gigante, G, Bartezaghi, M, Franchi, M, Ursoleo, P, Aloisi, E, Russo, Filomena, Galluzzo, Marco, Stingeni, Luca, Persechino, Severino, Zichichi, Leonardo, Conti, Andrea, Giofrè, Claudia, Dini, Valentina, Vispi, Martina, Atzori, Laura, Cattaneo, Angelo, Parodi, Aurora, Bardazzi, Federico, Stinco, Giuseppe, Dapavo, Paolo, Girolomoni, Giampiero, Musumeci, Maria Letizia, Papini, Manuela, Venturini, Marina, Dastoli, Stefano, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Pagnanelli, Gianluca, Bernardini, Nicoletta, Gambini, Daniele, Malagoli, Piergiorgio, Mazzatenta, Carlo, Peris, Ketty, Zalaudek, Iris, Fabbrocini, Gabriella, Loconsole, Francesco, Vassallo, Camilla, Pietroleonardo, Lucia, Prignano, Francesca, Franchi, Chiara, Offidani, Anna Maria, Bonifati, Claudio, Di Lernia, Vito, Gigante, Giovanni, Bartezaghi, Marta, Franchi, Matteo, Ursoleo, Paola, and Aloisi, Elisabetta

Abstract

Purpose: SUPREME, a phase IIIb study conducted in Italy, demonstrated safety and high efficacy of secukinumab for up to 72 weeks in patients with moderate-to-severe plaque-type psoriasis. SUPREME 2.0 study aimed to provide real-world data on the long-term drug survival and effectiveness of secukinumab beyond 72 weeks. Patients and Methods: SUPREME 2.0 is a retrospective observational chart review study conducted in patients previously enrolled in SUPREME study. After the end of the SUPREME study, eligible patients continued treatment as per clinical practice, and their effectiveness and drug survival data were retrieved from medical charts. Results: Of the 415 patients enrolled in the SUPREME study, 297 were included in SUPREME 2.0; of which, 210 (70.7%) continued secukinumab treatment throughout the 42-month observation period. Patients in the biologic-naïve cohort had higher drug survival than those in the biologic-experienced cohort (74.9% vs 61.7%), while HLA-Cw6–positive and HLA-Cw6–negative patients showed similar drug survival (69.3% and 71.9%). After 42 months, Psoriasis Area and Severity Index (PASI) 90 was achieved by 79.6% of patients overall; with a similar proportion of biologic-naïve and biologic-experienced patients achieving PASI90 (79.8% and 79.1%). The mean absolute PASI score reduced from 21.94 to 1.38 in the overall population, 21.90 to 1.24 in biologic-naïve and 22.03 to 1.77 in biologic-experienced patients after 42 months. The decrease in the absolute PASI score was comparable between HLA-Cw6–positive and HLA–Cw6-negative patients. The baseline Dermatology Life Quality Index scores also decreased in the overall patients (10.5 to 2.32) and across all study sub-groups after 42 months. Safety was consistent with the known profile of secukinumab, with no new findings. Conclusion: In this real-world cohort study, secukinumab showed consistently high long-term drug survival and effectiveness with a favourable safety profile.

Published
2023

5. Coronavirus disease 2019 (COVID-19) rash in a psoriatic patient treated with Secukinumab: Is there a role for Interleukin 17?

Author

Carugno, A, Gambini, D, Raponi, F, Vezzoli, P, Robustelli Test, E, Arosio, M, Callegaro, A, Sena, P, Carugno A., Gambini D. M., Raponi F., Vezzoli P., Robustelli Test E., Arosio M. E. G., Callegaro A., Sena P., Carugno, A, Gambini, D, Raponi, F, Vezzoli, P, Robustelli Test, E, Arosio, M, Callegaro, A, Sena, P, Carugno A., Gambini D. M., Raponi F., Vezzoli P., Robustelli Test E., Arosio M. E. G., Callegaro A., and Sena P.

Published
2020

6. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

Author

Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Belloni Fortina, A, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Venturini, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nistico, S, Giustini, S, Carugno, A, Cannavo, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Balestri, R, Bernardini, N, Botti, E, Burlando, M, Caldarola, G, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, M, Fidanza, R, Foti, C, Gambini, D, Gambardella, A, Girolomoni, G, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, M, Patrizi, A, Pellacani, G, Piaserico, S, Richetta, A, Rosi, E, Rossi, M, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Vezzoni, R, Zangrilli, A, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A. V., Potenza C., Conti A., Parodi A., Belloni Fortina A., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Venturini M., Bongiorno M. R., Feliciani C., Rubegni P., Amerio P., Fargnoli M. C., Pigatto P., Savoia P., Nistico S. P., Giustini S., Carugno A., Cannavo S. P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., Peris K., Balestri R., Bernardini N., Botti E., Burlando M., Caldarola G., Cattaneo A., Dapavo P., Dastoli S., De Simone C., Di Nuzzo S., Diotallevi F., Fierro M. T., Fidanza R., Foti C., Gambini D. M., Gambardella A., Girolomoni G., Guarneri C., Gualdi G., Hansel K., Megna M., Mugheddu C., Musumeci M. L., Patrizi A., Pellacani G., Piaserico S., Richetta A. G., Rosi E., Rossi M. T., Sacchelli L., Tiberio R., Tilotta G., Trovato E., Vezzoni R., Zangrilli A., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Belloni Fortina, A, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Venturini, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nistico, S, Giustini, S, Carugno, A, Cannavo, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Balestri, R, Bernardini, N, Botti, E, Burlando, M, Caldarola, G, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, M, Fidanza, R, Foti, C, Gambini, D, Gambardella, A, Girolomoni, G, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, M, Patrizi, A, Pellacani, G, Piaserico, S, Richetta, A, Rosi, E, Rossi, M, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Vezzoni, R, Zangrilli, A, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A. V., Potenza C., Conti A., Parodi A., Belloni Fortina A., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Venturini M., Bongiorno M. R., Feliciani C., Rubegni P., Amerio P., Fargnoli M. C., Pigatto P., Savoia P., Nistico S. P., Giustini S., Carugno A., Cannavo S. P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., Peris K., Balestri R., Bernardini N., Botti E., Burlando M., Caldarola G., Cattaneo A., Dapavo P., Dastoli S., De Simone C., Di Nuzzo S., Diotallevi F., Fierro M. T., Fidanza R., Foti C., Gambini D. M., Gambardella A., Girolomoni G., Guarneri C., Gualdi G., Hansel K., Megna M., Mugheddu C., Musumeci M. L., Patrizi A., Pellacani G., Piaserico S., Richetta A. G., Rosi E., Rossi M. T., Sacchelli L., Tiberio R., Tilotta G., Trovato E., Vezzoni R., and Zangrilli A.

Published
2020

8. COVID-19 and biologics for psoriasis: A high-epidemic area experience—Bergamo, Lombardy, Italy

Author

Carugno, A, Gambini, D, Raponi, F, Vezzoli, P, Locatelli, A, Di Mercurio, M, Robustelli Test, E, Sena, P, Carugno A., Gambini D. M., Raponi F., Vezzoli P., Locatelli A. G. C., Di Mercurio M., Robustelli Test E., Sena P., Carugno, A, Gambini, D, Raponi, F, Vezzoli, P, Locatelli, A, Di Mercurio, M, Robustelli Test, E, Sena, P, Carugno A., Gambini D. M., Raponi F., Vezzoli P., Locatelli A. G. C., Di Mercurio M., Robustelli Test E., and Sena P.

Published
2020

9. Cutaneous lupus erythematosus patients in a high-epidemic COVID-19 area, Bergamo, Italy

Author

Vezzoli, P, Di Mercurio, M, Carugno, A, Gambini, D, Robustelli Test, E, Imberti, G, Castagna, A, Sena, P, Vezzoli P., Di Mercurio M., Carugno A., Gambini D. M., Robustelli Test E., Imberti G., Castagna A. F., Sena P., Vezzoli, P, Di Mercurio, M, Carugno, A, Gambini, D, Robustelli Test, E, Imberti, G, Castagna, A, Sena, P, Vezzoli P., Di Mercurio M., Carugno A., Gambini D. M., Robustelli Test E., Imberti G., Castagna A. F., and Sena P.

Published
2020

10. Antonieta Rivas Mercado (1900-31), protagonista de la historia cultural mexicana.

Author

Zizi, D, Succio, M, Secchi, D, Sanfelici, L, De Llera, L, Pecellín, M, González Luna C, AM, Gambini, D, Flores Requejo, MJ, Fiore, A, Durante, L, Cassani, A, Andrés-Gallego, J., Gonzalez Luna Corvera, A, Gonzalez Luna Corvera, AM, Zizi, D, Succio, M, Secchi, D, Sanfelici, L, De Llera, L, Pecellín, M, González Luna C, AM, Gambini, D, Flores Requejo, MJ, Fiore, A, Durante, L, Cassani, A, Andrés-Gallego, J., Gonzalez Luna Corvera, A, and Gonzalez Luna Corvera, AM

Abstract

Protagonista indiscussa della vita culturale del Messico post-rivoluzionario, Antonieta Rivas Mercado (Città del Messico 1900 - Parigi 1931) - studiosa, scrittrice, traduttrice, attrice, promotrice, attivista - fa parte di una generazione di donne che hanno segnato la vita artistica e letteraria del Paese. Una figura femminile brillante e contraddittoria che può essere compresa solo da una doppia prospettiva, biografica e letteraria, in un dialogo con i suoi scritti autobiografici, i saggi e i testi di finzione che riflettono la scissione tra la sua vita pubblica e quella privata. Una vita la cui tragica fine ha offuscato la sua complessa biografia e ha alimentato la costruzione della leggenda della donna che si è suicidata per amore., An undisputed protagonist of the cultural life of post-revolutionary Mexico, Antonieta Rivas Mercado (Mexico City 1900 - Paris 1931) - a writer, translator, actress, promoter and activist - was part of a generation of women who marked the artistic and literary life of Mexico. A brilliant and contradictory female figure who can only be understood from a double perspective, biographical and literary, in a dialogue with her autobiographical writings, essays and fictional texts that reflect the cision between her public and private life. A life whose tragic end obfuscated her complex biography and fed the construction of the legend of the woman who committed suicide for love., Protagonista indiscutible de la vida cultural del México posrevolucionario, Antonieta Rivas Mercado (Ciudad de México 1900 – París 1931) -mecenas, escritora, traductora, actriz, promotora, activista- formó parte de una generación de mujeres que marcaron la vida artística y literaria nacional. Una figura femenina brillante y contradictoria que puede entenderse solo desde una doble perspectiva, biográfica y literaria, en un diálogo con sus escritos autobiográficos, ensayos y textos de ficción que reflejan la cisión existente entre su vida pública y privada. Una vida cuyo final trágico ofuscó su compleja biografía y alimentó la construcción de la leyenda de la mujer suicida por amor.

Published
2022

14. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

Author

Talamonti, M., Galluzzo, M., Chiricozzi, Andrea, Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Belloni Fortina, A., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Venturini, M., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nistico, S. P., Giustini, S., Carugno, A., Cannavo, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, Ketty, Balestri, R., Bernardini, N., Botti, E., Burlando, M., Caldarola, Giacomo, Cattaneo, A., Dapavo, P., Dastoli, S., De Simone, Clara, Di Nuzzo, S., Diotallevi, F., Fierro, M. T., Fidanza, R., Foti, C., Gambini, D. M., Gambardella, A., Girolomoni, G., Guarneri, C., Gualdi, G., Hansel, C., Megna, M., Mugheddu, C., Musumeci, M. L., Patrizi, A., Pellacani, G., Piaserico, S., Richetta, A. G., Rosi, E., Rossi, M. T., Sacchelli, L., Tiberio, R., Tilotta, G., Trovato, E., Vezzoni, R., Zangrilli, A., Chiricozzi A. (ORCID:0000-0002-6739-0387), Peris K. (ORCID:0000-0002-5237-0463), Caldarola G. (ORCID:0000-0002-8837-9232), De Simone C. (ORCID:0000-0002-0898-0045), Talamonti, M., Galluzzo, M., Chiricozzi, Andrea, Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Belloni Fortina, A., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Venturini, M., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nistico, S. P., Giustini, S., Carugno, A., Cannavo, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, Ketty, Balestri, R., Bernardini, N., Botti, E., Burlando, M., Caldarola, Giacomo, Cattaneo, A., Dapavo, P., Dastoli, S., De Simone, Clara, Di Nuzzo, S., Diotallevi, F., Fierro, M. T., Fidanza, R., Foti, C., Gambini, D. M., Gambardella, A., Girolomoni, G., Guarneri, C., Gualdi, G., Hansel, C., Megna, M., Mugheddu, C., Musumeci, M. L., Patrizi, A., Pellacani, G., Piaserico, S., Richetta, A. G., Rosi, E., Rossi, M. T., Sacchelli, L., Tiberio, R., Tilotta, G., Trovato, E., Vezzoni, R., Zangrilli, A., Chiricozzi A. (ORCID:0000-0002-6739-0387), Peris K. (ORCID:0000-0002-5237-0463), Caldarola G. (ORCID:0000-0002-8837-9232), and De Simone C. (ORCID:0000-0002-0898-0045)

Abstract

N/A

Published
2020

22. Abstract P2-08-21: Mismatch repair protein loss is a prognostic and predictive biomarker in breast cancers regardless of microsatellite instability

Author

Fusco, N, primary, Lopez, G, additional, Corti, C, additional, Pesenti, C, additional, Colapietro, P, additional, Ercoli, G, additional, Gaudioso, G, additional, Faversani, A, additional, Gambini, D, additional, Despini, L, additional, Blundo, C, additional, Vaira, V, additional, Miozzo, M, additional, Ferrero, S, additional, and Bosari, S, additional

Published
2019
Full Text
View/download PDF

23. Abstract P1-12-09: Proposal for integrating the pathologic assessment of lymphovascular invasion and extranodal tumor extension in breast cancer-related lymphedema clinical management

Author

Fusco, N, primary, Corti, C, additional, Lopez, G, additional, Michelotti, A, additional, Despini, L, additional, Gambini, D, additional, Lorenzini, D, additional, Guerini-Rocco, E, additional, Maggi, S, additional, Noale, M, additional, and Invernizzi, M, additional

Published
2019
Full Text
View/download PDF

28. Natural killer and t-cell cytotoxic cutaneous lymphomas

Author

BERTI, EMILIO, Gambini, D, Lucioni, M, Paulli, M., Berti, E, Gambini, D, Lucioni, M, and Paulli, M

Subjects
MED/15 - MALATTIE DEL SANGUE, MED/35 - MALATTIE CUTANEE E VENEREE, cutaneous NK/T lymphomas, cutaneous cytotoxic lymphomas, MED/08 - ANATOMIA PATOLOGICA
Abstract

In the group of primary cutaneous T-cell lymphomas, T-cytotoxic and natural killer cell lymphomas have been recently recognized as distinct and rare clinicopathologic entities. Typically, cytotoxic granules associated proteins TIA-1, granulolysine and perform, and cytotoxic-natural killer (NK) cell markers CD8+, CD56+, CD94+, CD161+, NKp46+ are expressed by tumoral cells. Five T-cytotoxic and NK cutaneous lymphomas subtypes are actually recognized: subcutaneous panniculitis-like T-cell lymphoma, extranodal nasal and nasal-type NK-T cell lymphoma, blastic NK cell lymphoma, aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma, cutaneous gamma-delta peripheral T-cell lymphoma. In this review, the most important clinical, histological, immunohistochemical and molecular data are analyzed together with differential diagnostic aspects between these entities. T-cytotoxic and NK cutaneous lymphomas pursue a very aggressive course, with poor outcome and high mortality rate, with few exceptions.

Published
2005

29. MANAGEMENT OF LEAD POISONING OF ADULT PATIENTS: EXPERIENCE OF THE POISON CENTRE OF MARSEILLES BETWEEN 1993 AND 2000

Author

De Haro, L, Prost, N, Gambini, D, Bourdon, JH, Hayek, M, Valli, M, Jouglard, J, and Arditti, J

Subjects
Lead poisoning -- Case studies, Poison control centers -- Reports, Environmental issues, Health, Pharmaceuticals and cosmetics industries
Abstract

Objective: Lead poisoning can occur in adults from occupational or environmental sources. In order to evaluate the chelation therapy provided in the poison Centre of Marseilles (PCM), the authors studied the cases of adult patients who consulted the PCM between 1993 and 2000 with a history of lead exposure. Method: In order to establish the diagnosis of chronic lead poisoning, EDTA provocation test was used: A lead blood level was done followed by an infusion of EDTA. A 24 hours urine collection was done to evaluate lead elimination. If the test was positive chelation therapy was given. Case Series: 45 cases were studied (9 women, 36 men, average age 44 y). The lead sources had occupational origins for 76% of the cases (welding, heavy metal industries, etc.), and environmental origins for 24% (shooting as a hobby, hunting, etc.). 91% of the patients presented with a clinical feature of possible lead intoxication (asthenia, abdominal pain, anaemia, seizures, etc). For 22 patients, EDTA provocation test was negative (average LBL 156 [micro]g/L - mini 50 [micro]g/L, maxi 555 [micro]g/L-and average LUE 277 [micro]g/24H post infusion-mini 20 [micro]g/24H, maxi 844 [micro]g/24H). 6 patients with a positive test refused to be treated (average LBL 365 [micro]g/L -mini 50 [micro]g/L, maxi 760 [micro]g/ L-and average LUE 3137 [micro]g/24H-mini 1279 [micro]g/24H, maxi 6236 [micro]g/24H). 16 patients with a positive test were treated with chelation therapy (average LBL 566 [micro]g/L-mini 320 [micro]g/L, maxi 943 [micro]g/L-and average LUE 3011 [micro]g/24H-mini 789 [micro]g/24H, maxi 7229 [micro]g/24H). 58 treatments were given (1 to 12 courses for each patient). The average quantities of lead eliminated in the urine during the chelation therapy was 30912 [micro]g [+ or -] 29059 [micro]g by case. In 12 patients who stopped the lead exposure after the diagnosis of lead poisoning, the chelation therapy decreased the LBL of 69%. In 4 patients still exposed during the treatment, the LBL decreased 7% only. In the 16 treated patients, a clinical improvement was noted, and no adverse effect of EDTA chelation therapy was observed during the 58 treatments. Conclusion: EDTA chelation therapy is a well tolerated treatment which has a good effect on lead poisoning symptoms. De Haro L, Prost N, Gambini D, Bourdon JH, Hayek M, Valli M, Jouglard J, Arditti J. Centre Antipoison, Hopital Salvator, Marseille, France

Published
2001

30. Increased hyperglycaemia during cotreatment with pentamidine and corticosteroids in AIDS patients

Author

Gambini, D, Brambilla, A. M, Galli, C, CASTAGNA, ANTONELLA, Veglia, F, LAZZARIN, ADRIANO, Gambini, D, Brambilla, A. M, Galli, C, Castagna, Antonella, Veglia, F, and Lazzarin, Adriano

Subjects
Acquired Immunodeficiency Syndrome, Pneumonia, Pneumocysti, Hyperglycemia, Trimethoprim, Sulfamethoxazole Drug Combination, Drug Therapy, Combination, Adrenal Cortex Hormone, Methylprednisolone, AIDS-Related Opportunistic Infection, Pentamidine, Trimethoprim, Human
Published
1997

33. Three cases of primary cutaneous lymphoblastic lymphoma: microarray-based comparative genomic hybridization and gene expression profiling studies with review of literature

Author

Vezzoli, P, Novara, F, Fanoni, D, Gambini, D, Balice, Y, Venegoni, L, Paulli, M, Crosti, C, Berti, E, BERTI, EMILIO, Vezzoli, P, Novara, F, Fanoni, D, Gambini, D, Balice, Y, Venegoni, L, Paulli, M, Crosti, C, Berti, E, and BERTI, EMILIO

Abstract

Lymphoblastic lymphoma (LBL) is a neoplasm of precursor B- or T-lymphocytes, and primary skin involvement is uncommon. The aim of the study was to review all reported primary cutaneous (PC)-LBLs and to examine three new cases to better characterize this neoplasm. Two of our patients showed a pre-B phenotype (PC-B-LBL) and one a never-reported pre-T phenotype (PC-T-LBL). The patient with PC-T-LBL showed an aggressive course, while those with PC-B-LBL showed a complete remission (CR) after polychemotherapy. Cytogenetic analysis and gene expression profiling (GEP) were performed on one case of PC-B-LBL and on that of PC-T-LBL. A specimen of PC-B-LBL and two specimens (early and late stage) of PC-T-LBL were investigated by microarray-based comparative genomic hybridization (CGH). All specimens revealed trisomy of chromosome 4. PC-T-LBL showed a gain of 1p36.33-p22.1 in the early stage and multiple chromosome gains/losses in the late stage. Our data suggest that trisomy 4 could be detected early in LBL and gain of 1p36.33-p22.1 could be an interesting marker in PC-T-LBL. LBL is an aggressive disease but, only in B-LBL, the cutaneous presentation seems to be a favorable prognostic factor and polychemotherapy is the best therapeutic approach. We suggest that PC-LBL should be included as a provisional clinicopathologic entity in future cutaneous lymphoma classification. © 2012 Informa UK, Ltd.

Published
2012

34. Mycoplasma genitalium in males with nongonococcal urethritis: prevalence and clinical efficacy of eradication.

Author

Gambini D, Decleva I, Lupica L, Ghislanzoni M, Cusini M, Alessi E, Gambini, D, Decleva, I, Lupica, L, Ghislanzoni, M, Cusini, M, and Alessi, E

Abstract

Background: Mycoplasma genitalium is regarded as a potential pathogen of the human urogenital tract based on prevalence findings of several European studies.Goal: To determine the prevalence of M genitalium in urethral specimens of symptomatic patients with nongonococcal urethritis and from asymptomatic patients attending a sexually transmitted disease clinic in Milan, and to verify the clinical efficacy of M genitalium eradication by antibiotic treatment.Study Design: From May 1998 to late April 1999, a routine analysis for M genitalium by DNA amplification (polymerase chain reaction) was performed in patients attending the Institute of Dermatological Science in Milan. The authors examined urethral swabs from 178 symptomatic and 23 asymptomatic males. M genitalium-positive patients were clinically and microbiologically tested after treatment with either doxycycline or azithromycin.Results: Among males with nongonococcal urethritis, M genitalium was detected in 14.0% of patients as the only agent; in 15.1% of patients in association with Chlamydia trachomatis and/or Ureaplasma urealyticum; and in 1 asymptomatic patient. In all symptomatic M genitalium-positive patients, antibiotic treatment eradicated the infection and cured clinical symptoms.Conclusion: These data reveal the high prevalence of M genitalium in symptomatic patients, the rarity of asymptomatic carriers, the high susceptibility to antibiotic treatment, and the clinical efficacy of M genitalium eradication. Moreover, data confirm the etiologic role of M genitalium in inflammatory processes of the human urogenital tract in the Mediterranean area. [ABSTRACT FROM AUTHOR]

Published
2000
Full Text
View/download PDF

35. Primary cutaneous follicular center cell lymphoma of the nose with maxillary sinus involvement in a pediatric patient

Author

Ghislanzoni, M, Gambini, D, Perrone, T, Alessi, E, Berti, E, BERTI, EMILIO, Ghislanzoni, M, Gambini, D, Perrone, T, Alessi, E, Berti, E, and BERTI, EMILIO

Abstract

We report a primary cutaneous follicular center cell lymphoma (PCFCCL) that arose on the nose and the left naso-labial fold, spread to the left cheek, the left maxillary sinus, and the soft palate in a 16-year-old boy. Polychemotherapy was performed and the patient is disease-free after 41 months. This case is unusual because PCFCCL rarely arises on the nose, only occasionally disseminates to extracutaneous sites, and, to our knowledge, has never been described in pediatric patients.

Published
2005

36. Natural killer and t-cell cytotoxic cutaneous lymphomas

Author

Berti, E, Gambini, D, Lucioni, M, Paulli, M, BERTI, EMILIO, Paulli, M., Berti, E, Gambini, D, Lucioni, M, Paulli, M, BERTI, EMILIO, and Paulli, M.

Abstract

In the group of primary cutaneous T-cell lymphomas, T-cytotoxic and natural killer cell lymphomas have been recently recognized as distinct and rare clinicopathologic entities. Typically, cytotoxic granules associated proteins TIA-1, granulolysine and perform, and cytotoxic-natural killer (NK) cell markers CD8+, CD56+, CD94+, CD161+, NKp46+ are expressed by tumoral cells. Five T-cytotoxic and NK cutaneous lymphomas subtypes are actually recognized: subcutaneous panniculitis-like T-cell lymphoma, extranodal nasal and nasal-type NK-T cell lymphoma, blastic NK cell lymphoma, aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma, cutaneous gamma-delta peripheral T-cell lymphoma. In this review, the most important clinical, histological, immunohistochemical and molecular data are analyzed together with differential diagnostic aspects between these entities. T-cytotoxic and NK cutaneous lymphomas pursue a very aggressive course, with poor outcome and high mortality rate, with few exceptions.

Published
2005

37. Thalidomide treatment for hypertrophic cutaneous lupus erythematosus

Author

Gambini, D, Carrera, C, Passoni, E, Muratori, S, Berti, E, Caputo, R, Caputo, R., BERTI, EMILIO, Gambini, D, Carrera, C, Passoni, E, Muratori, S, Berti, E, Caputo, R, Caputo, R., and BERTI, EMILIO

Abstract

INTRODUCTION: In recent years numerous reports have been published regarding satisfactory thalidomide therapy for refractory chronic cutaneous lesions of lupus erythematosus (CCLE); to date, in the literature, there is just one report describing two patients affected by hyperkeratotic CCLE successfully treated with thalidomide. METHODS: Six patients affected by a hypertrophic/verrucous variant of CCLE were treated with thalidomide during the period October 1999 to December 2002 and their medical records were retrospectively reviewed. The initial dose of thalidomide was 100mg/die by mouth for all the cases, while the duration of therapy was variable among the patients. RESULTS: All six patients responded to treatment: two had partial resolution of the lesions and four achieved almost complete clearing of cutaneous disease. Response to treatment was seen in the first month of therapy in all the patients. Follow-up nerve conduction studies were negative but a patient had to discontinue the drug because of neurological problems. DISCUSSION/CONCLUSION: Our case series confirms the efficacy of a 'low-dose' thalidomide regimen in verrucous/hyperkeratotic CCLE, which is normally unresponsive to conventional treatment; in this setting, thalidomide should be kept in mind as an extremely valid therapeutic option despite the lack of prospective, randomized, double-blind, placebo-controlled studies.

Published
2004

47. Anti-endothelial cell antibodies and autoimmune diseases.

Author

Papa, N., Gambini, D., and Meroni, P.

Abstract

AECA represent a new family of autoantibodies detectable in systemic autoimmune diseases. Different findings support their poten-tial importance both from a diagnostic and a prognostic point of view: On the other hand, AECA do not display an absolute cell specificity, being crossreactive, at least in part, with other cell types and lack of disease specificity. Up to now, AECA determination are still matter of research but their clinical usefulness in autoimmune diseases could increase when simpler assays for the detection will be available. [ABSTRACT FROM AUTHOR]

Published
1994
Full Text
View/download PDF

48. Méthode de mesure de la fraction d'ejection ventriculaire gauche effective par association radiocardiographie-scintigraphie cardiaque. Son intérêt pour le calcul des régurgitations aortique et mitrale

Author

P. De Vernejoul, M. Fauchet, Jean Philippe Metzger, Gambini D, L. Barritault, and J.N. Rimbert

Subjects
Radiation, Nuclear Energy and Engineering, Radiology, Nuclear Medicine and imaging
Abstract

Resume Les auteurs proposent une methode radio-isotopique de mesure de la fraction d'ejection ventriculaire gauche effective. Cette mesure, associee a celle de la fraction d'ejection totale determinee par cineangiocardiographie ou autres techniques, permet de calculer la fraction de regurgitation totale dans les cas de valvulopathies gauches. La regurgitation aortique etant appreciee a partir de l'etude de la courbe de dilution aortique, nous pouvons differencier et evaluer les fuites mitrale et aortique chez le sujet valvulaire a regurgitation complexe gauche.

Published
1976

49. Characterization of the Endothelial Surface Proteins Recognized by Anti-Endothelial Antibodies in Primary and Secondary Autoimmune Vasculitis

Author

Papa, N. Del, Conforti, G., Gambini, D., Rosa, L. La, Tincani, A., D'Cruz, D., Khamashta, M., Hughes, G. R.V., Balestrieri, G., and Meroni, P. L.

Abstract

The antigenic structures recognized by anti-endothelial cell antibodies (AECA) in sera from 10 Wegener's granulomatosis (WG) and 12 systemic lupus erythematosus (SLE) patients with signs of vasculitis were characterized by immunoprecipitation of selectively radiolabeled surface membrane proteins from human umbilical vein endothelial cells. Electrophoretic analysis of the immunoprecipitated proteins revealed reactivities against endothelial antigens ranging in size from 200 to 25 kDa. AECA antigens were not cell specific, since the same sera also reacted, at least in part, with radiolabeled human fibroblast surface proteins. The majority of WG patients displayed a constant precipitation pattern of five proteins (180, 155, 125, 68, and 25 kDa). On the contrary, AECA from SLE sera reacted with a more heterogeneous series of endothelial proteins. A group of four proteins, however, was also found in the majority of SLE sera: 200, 180, 155, and 25 kDa. In addition, some endothelial antigens were immunoprecipitated only by WG (125 kDa) or by SLE sera (200 kDa), suggesting a different endothelial reactivity in different vasculitic processes. The reaction did not involve intracellular proteins as demonstrated by the lack of reactivity of SLE sera negative for AECA but positive for anti-cytoplasmic or anti-nuclear antibodies. These data confirming that AECA recognize surface endothelial determinants further support a potential pathogenetic role for these antibodies in autoimmune vasculitis. Copyright 1994, 1999 Academic Press

Published
1994
Full Text
View/download PDF

50. Applications biomédicales de la résonance magnétique

Author

Le Bihan, Denis, Gambini, D., Granier, R., Leterrier, F., Service NEUROSPIN (NEUROSPIN), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Service Hospitalier Frédéric Joliot (SHFJ), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, and Le Bihan, Denis

Subjects
[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
1983

Catalog

Books, media, physical & digital resources
See catalog results